Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EE Mitogen-activated protein kinase (MEK) inhibitors
L01EE02 Cobimetinib
D10615 Cobimetinib fumarate (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
MAPK/ MEK Inhibitors
Cobimetinib
D10615 Cobimetinib fumarate (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
DG01825 Cobimetinib
D10615 Cobimetinib fumarate
Drug classes [BR:br08332]
Antineoplastic
DG03137 MEK inhibitor
D10615 Cobimetinib fumarate
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10615
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10615
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10615
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10615
Drug groups [BR:br08330]
Antineoplastic
DG03137 MEK inhibitor
DG01825 Cobimetinib